Trial Profile
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary) ; Peginterferon lambda-1a (Primary) ; Ritonavir (Primary)
- Indications Hepatitis D
- Focus First in man; Therapeutic Use
- Acronyms LIFT; LIFT HDV
- 14 Nov 2023 Results of pooled analysis from LOWR-3 , LIMT-1 and LIFT-1, comparing different combinations of novel HDV therapies and assessing their anti-HDV effectiveness, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 27 Jun 2022 According to an Eiger BioPharmaceuticals media release, data from this study were presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2022.
- 26 Jun 2022 Results assessing to characterize HDV RNA, HBV DNA, HBsAg and ALT kinetics during and after lonafarnib and pegylated IFN-Lambda combination therapy, presented at The International Liver Congress 2022.